URINARY sCD14 AS A BIOMARKER FOR CORONARY ARTERY DISEASE

Abstract

Disclosed herein is a method for the detection or preliminary screening of coronary artery disease, including: obtaining a urine sample from a human subject suspected of having coronary artery disease; detecting a level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease; and comparing the detected level of sCD14 in the urine sample with a predetermined standard, wherein the level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease greater than the predetermined standard is indicative of the presence of coronary artery disease.

What is claimed is: 
     
         1 . A method for the detection or preliminary screening of coronary artery disease, comprising:
 obtaining a urine sample from a human subject suspected of having coronary artery disease;   detecting a level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease; and   comparing the detected level of sCD14 in the urine sample with a predetermined standard;   wherein the level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease greater than the predetermined standard is indicative of the presence of coronary artery disease.   
     
     
         2 . The method according to  claim 1 , wherein the level of sCD14 is determined using an antibody-based binding moiety which specifically binds to sCD14. 
     
     
         3 . The method according to  claim 2 , wherein the level of sCD14 is determined by multiplex immunoassay, enzyme linked immunosorbent assay, radioimmunoassay, immunoradiometric assay, fluorescent immunoassay, chemiluminescent immunoassay or immunonephelometry. 
     
     
         4 . The method according to  claim 2 , wherein the antibody-based binding moiety is an antibody. 
     
     
         5 . The method according to  claim 2 , wherein the binding of the antibody is labeled with a detectable label. 
     
     
         6 . The method according to  claim 5 , wherein the detectable label is selected from the group consisting of a radioactive label, a hapten label, a fluorescent label, a chemiluminescent label, an enzymatic label and an epitope tag. 
     
     
         7 . The method according to  claim 1 , wherein the level of urinary sCD14 is determined by enzyme linked immunosorbent assay, and the predetermined standard for sCD14 is 3.51 μg/mL. 
     
     
         8 . A method for the monitoring of coronary artery disease, comprising:
 periodically obtaining a urine sample from a human subject suspected of having coronary artery disease;   detecting a level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease; and   comparing the detected level of sCD14 in the urine sample with a predetermined standard;   wherein the level of sCD14 in the urine sample from the human subject suspected of having coronary artery disease greater than the predetermined standard is indicative of the presence of coronary artery disease.   
     
     
         9 . The method according to  claim 8 , wherein the level of sCD14 is determined using an antibody-based binding moiety which specifically binds to sCD14. 
     
     
         10 . The method according to  claim 9 , wherein the level of sCD14 is determined by multiplex immunoassay, enzyme linked immunosorbent assay, radioimmunoassay, immunoradiometric assay, fluorescent immunoassay, chemiluminescent immunoassay or immunonephelometry. 
     
     
         11 . The method according to  claim 9 , wherein the antibody-based binding moiety is an antibody. 
     
     
         12 . The method according to  claim 9 , wherein the binding of the antibody is labeled with a detectable label. 
     
     
         13 . The method according to  claim 12 , wherein the detectable label is selected from the group consisting of a radioactive label, a hapten label, a fluorescent label, a chemiluminescent label, an enzymatic label and an epitope tag. 
     
     
         14 . The method according to  claim 8 , wherein the level of urinary sCD14 is determined by enzyme linked immunosorbent assay, and the predetermined standard for sCD14 is 3.51 μg/mL.